ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
June 25, 2019Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery. -
Ocular Therapeutix crosses finish line with eye treatment after running down production problems
December 05, 2018After twice being sidelined by manufacturing-related CRLs, Ocular Therapeutix got FDA approval on Monday for its first eye drug. -
FDA Approves Dextenza
December 04, 2018FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery.Ocular Therapeutix™, Inc. a biopharmaceutical company focused .......
Pharma Sources Insight January 2025
